Evaluate the Effect of Abdominal Electrical Muscle Stimulation on Abdominal Wall Restoration in Post - Partum Women

Diastasis Recti Clinical Trial

Official title:

A Randomized Controlled Trial to Evaluate the Effect of Abdominal EMS (Electrical Muscle Stimulation) on AWR (Abdominal Wall Restoration) in Post - Partum Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03917160
• Other study ID #: DO608427A
• Status: Completed
• Phase: N/A
• Start date: March 27, 2019
• Est. completion date: October 1, 2021

Study information

• Verified date: October 2021
• Source: InMode MD Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to evaluate the safety and efficacy of Abdominal EMS (Electrical Muscle Stimulation) on AWR (Abdominal Wall Restoration) in Post - Partum Women

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 1, 2021
• Est. primary completion date: October 1, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• - Post-partum women aged 18-45 years with symptoms of diastasis recti and weakness of the linea alba

• Informed Consent Form signed by the subject.

• BMI interval: 18.5 = BMI = 32 (normal to overweight, but not obese).

• Willing to follow the treatment and follow-up schedule and post-treatment care instructions.

• Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.

• In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause).

Exclusion Criteria:

• - Unable to commit to future appointments

• Planning on moving away from the local area within 6 months

• History of other energy-based therapy within one year

• Diffuse pain syndrome or chronic pain requiring daily narcotics

• Active electrical implant/device in any region of the body, including pacemaker or internal defibrillator

• Permanent implant in the treated area such as metal plates, screws or silicon, metal piercing or other.

• Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles.

• Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.

• History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.

• History of bleeding coagulopathies or use of anticoagulants except for low-dose aspirin.

• Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.

• Impaired immune system due to immunosuppressive diseases such as AIDS and HIV or use of immunosuppressive medications.

• Pregnancy.

• Poorly controlled endocrine disorders, such as Diabetes, or thyroid dysfunction and hormonal virilization.

• Isotretinoin (Accutane) within last 6 months.

• Any active condition in the treatment area, such as sores, Psoriasis, eczema, and rash, open lacerations, abrasions or lesions, infection in the area to be treated, current urinary tract infection or pelvic infection, uterine prolapse, cystocele, rectocele.

• Any surgical procedure in the treatment area within the last 12 months or before complete healing.

• Having received treatment with light, laser, RF, or other devices in the treated area within 2-3 weeks for non-ablative procedures, and 6-12 weeks for ablative fractional laser resurfacing (according to treatment severity) prior to treatment, except special recommendations.

• Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) one week before and after each treatment session, as per the practitioner's discretion.

• As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.

• Any therapies or medications which may interfere with the use of the study device.

• Compromised health as determined by the study doctor.

Related Conditions & MeSH terms

• Abdominal Wall Restoration
• Diastasis Recti

Intervention

Device:
• EMS device
EMS treatment will be performed

Locations

Country	Name	City	State
United States	Southern Oklahoma Women's Health	Ardmore	Oklahoma
United States	Advanced Women's Care of the Lowcountry, PC	Bluffton	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
InMode MD Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in inter-recti distance (IRD), measured via Magnetic Resonance Imaging.	Up to 5 subjects will undergo MRI to evaluate effect of the treatment	1 month
Primary	Change in inter-recti distance (IRD), measured via UltraSound Imaging to evaluate effect of the treatment		1 Month, 3 Months, 6 Months
Secondary	Change in Urogynecological Complaints measured using the Pelvic Floor Distress Inventory.	Pelvic Floor Distress Inventory - The PFDI-20 is both a symptom inventory and a measure of the degree of bother and distress (quality-of-life) caused by pelvic floor symptoms.	1 Month, 3 Months, 6 Months
Secondary	Change in Severity of Lumbopelvic and/or Abdominal Pain measured by Visual Analog Scale.	Pain will be assessed based on the Numerical Scale Response (NSR).	1 Month, 3 Months, 6 Months
Secondary	Investigator satisfaction	Satisfaction assessment will be performed by the study investigator using using 0 - 4 -points Likert scale	1 Month, 3 Months, 6 Months
Secondary	Subject improvement and satisfaction	Improvement and satisfaction assessment will be performed independently by the subject using 0 - 4 -points Likert scale	1 Month, 3 Months, 6 Months